Low Concentrations of C5a Complement Receptor Antibodies Are Linked to Disease Activity and Relapse in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis

To examine concentrations of circulating antibodies targeting C3a and C5a complement receptors in antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis (AAV) and analyze their association with disease activity.

[1]  M. Prendecki,et al.  New Therapeutic Targets in Antineutrophil Cytoplasm Antibody–Associated Vasculitis , 2021 .

[2]  G. Riemekasten,et al.  Autoantibodies against C5aR1, C3aR1, CXCR3, and CXCR4 are decreased in primary Sjogren's syndrome. , 2021, Molecular immunology.

[3]  A. Kruse,et al.  Autoantibodies as Endogenous Modulators of GPCR Signaling. , 2020, Trends in pharmacological sciences.

[4]  Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.

[5]  M. Infantino,et al.  European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view , 2019, Annals of the Rheumatic Diseases.

[6]  J. Subra,et al.  Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. , 2019, Autoimmunity reviews.

[7]  Yichun Hu,et al.  Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.

[8]  Josef Spidlen,et al.  Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets , 2019, Nature Communications.

[9]  D. Gladman,et al.  2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus , 2019, Arthritis & rheumatology.

[10]  Robert B. Russell,et al.  Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy , 2019, The Journal of Biological Chemistry.

[11]  B. Engelhardt,et al.  GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis , 2018, Nature Communications.

[12]  V. Tesar,et al.  Avacopan in the treatment of ANCA-associated vasculitis , 2018, Expert opinion on investigational drugs.

[13]  G. Riemekasten,et al.  Autoantibodies in Serum of Systemic Scleroderma Patients: Peptide-Based Epitope Mapping Indicates Increased Binding to Cytoplasmic Domains of CXCR3 , 2018, Front. Immunol..

[14]  Min Chen,et al.  Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis , 2015, Arthritis Research & Therapy.

[15]  T. Schall,et al.  C5a receptor (CD88) blockade protects against MPO-ANCA GN. , 2014, Journal of the American Society of Nephrology : JASN.

[16]  Min Chen,et al.  Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[17]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.

[18]  F. Luft,et al.  C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[20]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[21]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[22]  C. Gordon,et al.  Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.